Azithromycin dihydrate is a macrolide antibiotic used for the treatment of several types of bacterial infections. The drug shows low oral bioavailability due to its low solubility. In this present work solid lipid nanoparticles of azithromycin dihydrate has been formulated, keeping in view to enhance the solubility and rate of dissolution of the drug.
Azithromycin dihydrate (AZT) is a new generation of macrolide antibiotics. It is an azalide with a 15-membered azalactone ring. It is derived from erythromycin and possess enhanced antimicrobial activity. It is prescribed for once daily dosing because of its long half-life. According to the Biopharmaceutical Classification System, Azithromycin dihydrate can be classified as a class II drug, therefore the a rate-limiting step in the process of drug absorption is the dissolution of the drug which accounts for its low bioavailability 6, 7 . Furthermore, it is a substrate of p-glycoprotein (p-gp) transport system which is further responsible for its low bioavailability due to ileal clearance (biliary plus intestinal excretion clearance) 8, 9 . Therefore, the present investigation aims to prepare and characterize azithromycin loaded solid lipid nanoparticles using stearic acid with different surfactant combinations with a view to improve solubility of azithromycin dihydrate. It can be used as an alternative carrier transport system to improve the dissolution and bioavailability of azithromycin dihydrate. 
MATERIALS AND METHODS

Materials
Azithromycin dihydrate was a gift sample from Strides Ltd, Bangalore. Stearic acid was procured from Loba Chemicals Pvt. Ltd, Mumbai, India. Tween-20 was procured from SD Fine-Chem Ltd. Poloxamer 188 and polaxamer 407 were received from Dr.
Reddys laboratories. All other reagents and solvent used were of analytical grade.
Methods
Preparation of Azithromycin dihydrate SLNPs by high shear homogenization method
The solid lipid nanoparticles of Azithromycin dihydrate were prepared using stearic acid and different surfactants at varied proportion by high shear homogenization technique 10 . Table 1 
Evaluation of solid lipid nanoparticles
Drug content
For determining drug content, 250mg of SLN was weighed accurately and dissolved in phosphate buffer pH 6.0 up to 250ml. 1ml was taken and diluted to 100ml with phosphate buffer pH 6.0 and the solution was analyzed spectrophotometrically at 482nm, using 13.5 mol/L sulfuric acid as color developing agent. Percentage drug content was calculated using the formula 11 u n c o r r e c t e d
Absorbance of test Absorbance of Standard at the same dilution * 100
Determination of entrapment efficiency and Drug loading
The entrapment efficiency was determined by centrifugation method. SLN dispersion equivalent to 10 mg drug was centrifuged at 15,000 rpm for 60 min using Remi cooling centrifuge (Mumbai, India). The supernatant layer was diluted with phosphate buffer pH 6.0 and the absorbance was measured at 482 nm in UV VIS spectrophotometer (Shimadzu 1800, Japan) by using 13.5 mol/L sulfuric acid as color developing agent 12 . The percentage entrapment efficiency and percentage drug loading were calculated from the following equations 13, 14 .
%Entrapment efficiency Weight of initial drug Weight of free drug Weight of initial drug * 100 % Drug Loading Amount of entrapped drug in SLN Total weight of SLN * 100
In vitro dissolution studies
The invitro release of different SLN dispersion of azithromycin was carried out by using USP type II apparatus (paddle type). Formulation equivalent to 250 mg of drug was taken in the dissolution chamber containing 900ml of phosphate buffer pH 6.0.
The temperature of dissolution chamber was maintained at 37ᴼC±0.5ᴼC, the samples were withdrawn at predetermined intervals for 45min and the same were replenished with fresh buffer to maintain the sink condition. Drug content of each sample was determined spectrophotometrically at 482nm after suitable dilution with phosphate buffer pH 6.0 with 13.5 mol/L sulfuric acid as color developing agent. The amount of drug released from the nanoparitcles were calculated 15 .
u n c o r r e c t e d p r o o f
Particle size analysis
The mean particle size and polydispersity index (PDI) were determined by dynamic light scattering (DLS) principle (Zetasizer nano ZS, Malvern Instruments, UK). Samples after appropriate dilutions in Milli Q water were taken for analysis 16 . Particle size analysis for the formulations were carried out following proper dilutions in Milli Q water at 25.1ºC with equilibration time 70 sec in triplicate.
Zeta potential analysis
Electrophoretic Light Scattering principle was used to carry out the electrophoretic mobility of nanoparticles using (Zetasizer nano ZS, Malvern Instruments, UK).
Measurements were carried out in triplicate at 25.1ºC using water as a dispersant (refractive index: 1.330) in a clear disposable zeta cell.
Scanning electron microscopy
To study the surface morphology scanning electron microscopy was done 17 . The study was carried out at low accelerating voltage of about 15KV with load current about 80mA and working distance WD=9.1mm using a SEM (Model JSM 840 A, Jeol, Japan).
Fourier Transform infrared spectroscopy (FTIR)
The compatibility study of azithromycin dihydrate, stearic acid and the other surfactants were done by Attenuated Total Reflection technique (ATR) at ambient temperature using Bruker Model Alpha E (USA) through direct sampling. The microfine powered drug was sprinkled on the ATR crystal. This facilitated the refraction. The FTIR spectra of the physical mixture of drug and excipients thus obtained, ascertained the compatibility of the drug with the excipients 18 .
Stability studies u n c o r r e c t e d p r o o f
The nanoparticles of azithromycin dihydrate were stored in capped glass vials at 40ᴼC ± 2ᴼC /75% RH ± 5% RH for 90 days. Samples were evaluated periodically for its particle size, drug content and % release at the end of 30, 60 and 90 days 14 .
Differential Scanning Calorimetric (DSC) study
The DSC thermogram of pure drug, stearic acid, blank formulation and azithromycin dihydrate loaded SLNs were recorded by using Mettler-Toledo DSC (Mumbai, India). A suitable quantity of sample was weighed and heated in a closed pierced aluminum pan at a scanning rate of 10°C/min between 30-200°C and 20 ml/min of nitrogen flow.
RESULTS AND DISCUSSION
Drug content
The drug content of nanoparticles of azithromycin dihydrate were found in the range of 88.03 to 97.86%. The high shear homogenization method for preparing solid lipid nanoparticles of azithromycin with varied proportion of stearic acid and different surfactants at their different concentration found to be effective. The results are summarized in Table 2 .
Entrapment efficiency and Drug loading
To achieve high entrapment of drug in the different concentration of lipid matrix of stearic acid, the type and concentration of surfactants were varied in the ratio between 1:1 to 2:1. It was observed that as the drug was moderately lipophilic the entrapment efficiency of the drug in the matrix was highly satisfactory. The range of the percentage entrapment and drug loading was found to be in the range between 69 to 89% and 23 to 30 % respectively and is summarized in Table 2 . showed comparatively better release than any other formulations. This may be attributed to the effect of concentration of surfactant on the physical properties of the nanoparticles. Poloxamer 188 was found to be the best probably for its low molecular weight, thereby low viscosity and high HLB compared to other surfactants which enhanced the release of drug from the lipid matrix 19, 20 .
Particle size, Polydispersity index and Zeta potential measurement
Azithromycin dihydrate loaded SLN which showed highest entrapment efficiency and drug release were subjected to further characterization of particle size, zeta potential and polydispersity index as shown in Table 3 . The selected formulations showed a mean particle size between 143 and 167 nm. The particles were in an acceptable nanometer range, favored for lymphatic uptake. The poly dispersity index less than 1 indicated that the formulations were monodisperse in system. Estimation of Zeta potential helps in determining surface charge and potential stability of the dispersed system. Usually high positive or negative zeta potential is required for SLN as the same charge results in electrostatic repulsion thereby avoids aggregation of particles.
The zeta potential of the selected formulations F2, F6 and F10 was found to be -30.1mV, -31.8mV, and -30.6mV respectively.
Scanning electron microscopy u n c o r r e c t e d p r o o f
The surface morphology of the SLN s was studied by SEM. Formulations F2, F6
and F10 were subjected for size and morphology study. The photographs ( Figure 4 , 5 and 6) revealed that all particles were discrete entities, slightly spherical in shape with a smooth surface. So the employed method of preparation of SLN by hot homogenization was found to be appropriate for formulation of nanoparticles.
FTIR Studies
The FTIR spectrum of pure azithromycin dihydrate showed the characteristic peaks at The FTIR spectra of the 1:1 physical mixtures of drug, stearic acid and surfactants had all the characteristic peak ( Figure 7 ) and the band values of azithromycin dihydrate confirming that all the fuctional groups were well preserved.
This study clearly indicated the absence of any chemical interaction between the drug and the excipients, and they were compatible to each other.
Stability studies
The selected formulations were subjected to short term stability studies for a period of 90 days at 40ᴼC ± 2ᴼC /75% ± 5% RH. Both physical and chemical changes were observed during the study at an interval of 30 days. Physical stability was analyzed in terms of particle size whereas chemical stability was analyzed by the determination of drug content and change in the release profile. The drug content was found to be 93.21%, 97.53 % and 97.11 % for formulation F2, F6 and F10 respectively at the end of the study. Figure 8 and 9 revealed that all the formulations retained their size and release profile during the study period. Therefore, the formulations were found to be stable at 40ᴼC ± 2ᴼC /75% ± 5% RH.
DSC studies u n c o r r e c t e d p r o o f
Differential scanning calorimetry was used to investigate the thermal behavior of the pure drug in the lipid surfactant mixture. Azithromycin dihydrate showed an endothermic peak at 115.77°C with onset at 93.11°C and end set at 125.54°C that corresponds to the melting point of Azithromycin dihydrate as shown in Figure 10 (A). It was noticed that there was a shift in the melting point from 115.77°C to 47.07°C (Figure 10 B) indicating that Azithromycin dihydrate must be molecularly dispersed in the formulations 21 . The complete fusion of drug in the matrix was further proved by the thermograms of pure stearic acid and blank SLN corresponds to F6 as shown in Figure   11 . 
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